Clinical stage leverage Highlight opportunities to partner with ZZ Biotech on late-stage development, regulatory strategy, and potentially co-development for 3K3A-APC in ischemic stroke and related neurological indications, leveraging their NIH-supported Phase 2 data and FDA Fast Track designation.

Wound care potential Explore licensing or collaboration for wound healing applications such as diabetic foot ulcers, burns, and inflammatory skin disorders, where their APC-based therapies and patents could complement current wound management portfolios.

IP and patents Position partnerships around ZZ Biotech’s complementary patent suite on APC and APC mutants to extend protection in wound healing and inflammatory dermatology, offering a defensible path for joint development and exclusive rights in selected territories.

Funding and milestones Leverage their NIH NeuroNEXT-supported Phase 2 data and historical grant funding to align milestone-driven deals, grants-in-kind, or milestone-based financings with potential collaborators seeking validated neuroprotective assets.

Strategic fit Target mid to large biotech or pharma players with neurology and wound care portfolios seeking innovative biologics, KOL engagement, and fast-tracked development programs to accelerate portfolio diversification and therapeutic reach.